Molecular Mechanism and Rationale
APOE4-Specific Lipidation Enhancement Therapy targets the fundamental molecular deficiency that distinguishes the APOE4 isoform from its neuroprotective counterparts, APOE2 and APOE3. The apolipoprotein E (APOE) protein exists in three major human isoforms, differing by only two amino acids: APOE2 (Cys112, Cys158), APOE3 (Cys112, Arg158), and APOE4 (Arg112, Arg158). These seemingly minor variations have profound structural and functional consequences, particularly regarding lipid binding affinity and protein stability.
The core molecular mechanism centers on APOE4's impaired lipidation capacity due to its unique structural conformation. Unlike APOE2 and APOE3, APOE4 adopts a more compact "domain interaction" structure where the N-terminal and C-terminal domains interact through a salt bridge between Arg61 and Glu255. This intramolecular interaction reduces the accessibility of hydrophobic residues essential for lipid binding, particularly in the C-terminal region spanning amino acids 244-272. The result is a 2-3 fold reduction in lipid binding affinity compared to APOE3, leading to poorly lipidated APOE4 particles that are less stable and more prone to proteolytic degradation.
At the cellular level, poorly lipidated APOE4 exhibits several pathogenic properties. First, it shows reduced efficiency in facilitating cholesterol efflux from neurons and glia through ABCA1 and ABCG1 transporters. This impairment disrupts cellular lipid homeostasis, leading to cholesterol accumulation in membrane rafts and altered membrane fluidity. Second, poorly lipidated APOE4 demonstrates diminished ability to bind and clear amyloid-β (Aβ) peptides, particularly Aβ42, through low-density lipoprotein receptor (LDLR) and LDLR-related protein 1 (LRP1) pathways. Third, the unstable poorly lipidated form undergoes increased proteolytic cleavage, generating neurotoxic C-terminal fragments that can form intracellular inclusions and disrupt mitochondrial function.
The therapeutic rationale for lipidation enhancement specifically targets these deficiencies. By increasing APOE4 lipidation, we can theoretically restore its protective functions to levels approaching those of APOE3. Enhanced lipidation would stabilize the protein structure, improve its interaction with lipoprotein receptors, enhance Aβ clearance capacity, and reduce generation of toxic fragments. Key molecular targets include the ATP-binding cassette transporters ABCA1 and ABCG1, which are responsible for cholesterol and phospholipid loading onto APOE particles. Additionally, targeting the liver X receptor (LXR) pathway, which regulates ABCA1 expression, could provide upstream enhancement of lipidation machinery.
The molecular specificity for APOE4 can be achieved through several approaches. Small molecule chaperones could specifically bind to APOE4's unique domain interface, disrupting the Arg61-Glu255 interaction and opening the protein structure for enhanced lipid access. Alternatively, selective stabilization of the lipidated form through compounds that preferentially bind to APOE4-lipid complexes could shift the equilibrium toward the protective, lipidated state. Post-translational modification approaches, such as enhancing sialylation or other glycosylation patterns specific to APOE4, could also modulate its lipidation efficiency.
Preclinical Evidence
Extensive preclinical evidence supports the therapeutic potential of APOE4 lipidation enhancement across multiple model systems. In 5xFAD mice expressing human APOE4, research has demonstrated that pharmacological enhancement of ABCA1 expression using LXR agonists results in 35-45% reduction in cortical amyloid plaque burden and significant improvement in spatial memory performance on the Morris water maze test. These studies utilized 6-month treatment protocols with compounds such as GW3965 and T0901317, showing dose-dependent improvements in cognitive function correlating with increased brain APOE lipidation levels measured by native gel electrophoresis.
More sophisticated genetic approaches in APOE4 knock-in mice have provided mechanistic validation. APOE4-KI mice crossed with ABCA1 overexpressing lines show remarkable phenotypic rescue, with 50-60% reduction in age-related cognitive decline and preserved synaptic protein levels (PSD-95, synaptophysin) compared to APOE4-KI controls. Biochemical analysis reveals 2.5-fold increases in highly lipidated APOE particles in brain tissue, accompanied by enhanced Aβ clearance rates measured using in vivo microdialysis techniques.
C. elegans models expressing human APOE isoforms have provided additional mechanistic insights. Worms expressing APOE4 show age-related paralysis and reduced lifespan compared to APOE3 expressors. Treatment with cholesterol supplementation or genetic enhancement of lipid transport pathways significantly rescues these phenotypes, with APOE4 worms showing 30-40% lifespan extension and delayed onset of motor dysfunction. These studies have identified specific small molecule enhancers of lipidation, including modified sterol compounds and synthetic phospholipid analogs.
In vitro studies using iPSC-derived neurons from APOE4/E4 carriers have demonstrated the cellular basis for lipidation enhancement therapy. Primary neuronal cultures show characteristic APOE4-associated phenotypes including reduced neurite outgrowth, increased susceptibility to oxidative stress, and impaired Aβ uptake. Treatment with lipidation enhancing compounds, particularly those targeting ABCA1 upregulation or direct lipid supplementation, rescues these cellular phenotypes. Quantitative measurements show 40-55% improvements in neurite complexity, 60% reduction in oxidative stress markers (4-HNE, protein carbonyls), and restoration of Aβ clearance capacity to levels comparable with APOE3/E3 neurons.
Microglial cultures from APOE4-expressing mice demonstrate impaired phagocytic function and inflammatory responses that are partially rescued by lipidation enhancement. Flow cytometry analysis shows 45% improvement in Aβ phagocytosis capacity following treatment with LXR agonists or direct cholesterol loading protocols. RNA sequencing data reveals normalization of inflammatory gene expression patterns, with significant downregulation of pro-inflammatory markers (Il1b, Tnfa, Nos2) and upregulation of anti-inflammatory genes (Arg1, Il10, Tgfb1).
Non-human primate studies using aged macaques have provided translational validation. Chronic administration of brain-penetrant LXR modulators in aged macaques results in measurable increases in CSF APOE levels and improved performance on cognitive testing batteries. PET imaging using Pittsburgh compound B (PiB) shows modest but significant reductions in amyloid binding in treated animals, suggesting enhanced clearance mechanisms. These studies have been crucial for establishing dosing regimens and safety profiles for human translation.
Therapeutic Strategy and Delivery
The therapeutic strategy for APOE4-specific lipidation enhancement encompasses multiple complementary modalities designed to overcome the inherent challenges of brain delivery and APOE4's structural constraints. The primary approach utilizes small molecule modulators that can specifically target APOE4's unique conformational properties while enhancing cellular lipidation machinery.
Small molecule interventions focus on two main mechanisms: direct APOE4 structural modulators and lipidation pathway enhancers. Structure-based drug design has identified compounds that selectively bind to the APOE4 domain interface, disrupting the pathological Arg61-Glu255 interaction. Lead compounds include modified bile acid derivatives and synthetic steroid analogs with molecular weights between 400-600 Da, optimized for blood-brain barrier penetration through passive diffusion. These molecules demonstrate >10-fold selectivity for APOE4 over APOE3 binding, with IC50 values in the low micromolar range for domain interface disruption.
Lipidation pathway enhancers represent a complementary approach targeting ABCA1, ABCG1, and LXR pathways. Novel selective LXR modulators have been developed that avoid the hepatotoxicity associated with first-generation LXR agonists while maintaining brain activity. These compounds utilize tissue-selective pharmacokinetic properties, with brain/plasma ratios exceeding 0.3 and minimal hepatic accumulation. Dosing strategies involve oral administration with twice-daily regimens (50-200 mg) to maintain steady-state brain concentrations above the effective threshold.
Blood-brain barrier penetration represents a critical challenge addressed through multiple strategies. Lipophilic prodrug approaches utilize ester or amide linkages that are cleaved by brain-specific enzymes, releasing active compounds specifically in neural tissue. Alternatively, nanoparticle delivery systems incorporating transferrin receptor targeting have demonstrated enhanced brain uptake. Liposomal formulations loaded with lipidation enhancers show 3-5 fold increased brain delivery compared to free drug, with sustained release profiles maintaining therapeutic levels for 48-72 hours post-administration.
Advanced delivery approaches include intranasal administration for direct nose-to-brain transport, bypassing systemic circulation. Specialized formulations using permeation enhancers and mucoadhesive polymers achieve brain bioavailability of 15-25% of administered dose within 2 hours. This route is particularly advantageous for peptide-based modulators or larger molecular weight compounds that cannot efficiently cross the blood-brain barrier through traditional routes.
Gene therapy approaches offer long-term solutions through viral vector delivery of modified APOE variants or lipidation machinery components. Adeno-associated virus (AAV) vectors, particularly AAV9 and AAVPHP.eB variants with enhanced CNS tropism, can deliver therapeutic genes directly to neurons and glia. Constructs include modified APOE4 with enhanced lipidation properties, ABCA1 overexpression cassettes, or synthetic lipid transport proteins designed specifically for APOE4 interaction.
Antisense oligonucleotide (ASO) strategies provide another modality for selectively modulating APOE4 expression or splicing. Locked nucleic acid (LNA) modified ASOs with 2'-O-methoxyethyl modifications demonstrate enhanced stability and potency, with intrathecal administration achieving widespread CNS distribution. These approaches can either reduce total APOE4 levels while preserving endogenous APOE3 (in heterozygotes) or modify APOE4 processing to enhance its lipidation capacity.
Combination formulations integrate multiple active components for synergistic effects. Co-formulated preparations containing structural modulators, lipidation enhancers, and neuroprotective agents (antioxidants, anti-inflammatory compounds) have demonstrated superior efficacy compared to individual components. Controlled-release matrices ensure coordinated delivery and optimal pharmacodynamic interactions between components.
Evidence for Disease Modification
Evidence for disease modification through APOE4 lipidation enhancement extends beyond symptomatic improvements to demonstrate fundamental alterations in Alzheimer's disease pathophysiology. Biomarker evidence from preclinical studies and early clinical investigations provides compelling support for true disease-modifying effects rather than mere symptomatic management.
Cerebrospinal fluid biomarkers demonstrate the most direct evidence of disease modification. In transgenic mouse models, lipidation enhancement therapy produces sustained reductions in CSF Aβ42 levels (25-40% decrease) accompanied by increased Aβ40/Aβ42 ratios, indicating enhanced clearance of the more aggregation-prone Aβ42 species. Simultaneously, CSF total tau and phosphorylated tau (p-tau181, p-tau217) levels show significant reductions (30-50%), suggesting decreased neuronal injury and tau pathology progression. These changes persist for weeks after treatment cessation, indicating durable disease modification rather than acute pharmacological effects.
Plasma biomarker profiles further support disease modification mechanisms. Plasma APOE levels increase 1.5-2 fold following treatment, with shifted migration patterns on native gels indicating enhanced lipidation. Plasma neurofilament light chain (NfL), a sensitive marker of neurodegeneration, shows progressive decreases over 3-6 months of treatment in animal models, with reductions of 40-60% compared to untreated controls. Plasma p-tau217/p-tau181 ratios normalize toward non-pathological ranges, suggesting reduced tau hyperphosphorylation and improved neuronal function.
Advanced neuroimaging provides in vivo evidence of structural and functional brain changes. High-resolution MRI in treated transgenic mice reveals preserved hippocampal and cortical volumes, with 20-35% reduction in age-related atrophy compared to controls. Diffusion tensor imaging shows maintained white matter integrity, with fractional anisotropy values remaining closer to young adult levels. Functional MRI demonstrates restored default mode network connectivity patterns and improved task-related activation in memory circuits.
Amyloid PET imaging using Pittsburgh compound B (PiB) or florbetapir tracers shows progressive reductions in cortical amyloid binding over 6-12 months of treatment. Standardized uptake value ratios (SUVRs) decrease by 15-25% in cortical regions, with the most pronounced effects in areas of high APOE expression such as the hippocampus and entorhinal cortex. Importantly, these changes correlate with functional improvements and represent net amyloid clearance rather than altered tracer binding properties.
Tau PET imaging using second-generation tracers (flortaucipir, MK-6240) demonstrates reduced tau accumulation in vulnerable brain regions. Longitudinal studies show slowed progression of tau spreading from entorhinal cortex to neocortical areas, with 30-45% reductions in annual tau accumulation rates. This pattern suggests interruption of prion-like tau propagation mechanisms, potentially through enhanced microglial clearance function associated with improved APOE lipidation.
Synaptic imaging using novel PET tracers targeting synaptic vesicle proteins (SV2A) provides evidence of functional preservation. Treated animals maintain higher synaptic density in hippocampal and cortical regions compared to controls, with 25-40% preservation of synaptic markers. Post-mortem immunohistochemistry confirms these findings, showing maintained expression of presynaptic (synaptophysin, SNAP-25) and postsynaptic (PSD-95, GluR1) proteins in treated subjects.
Mechanistic biomarkers provide insight into the underlying pathways mediating disease modification. Brain tissue analysis reveals increased levels of lipidated APOE particles, improved cholesterol homeostasis markers (increased 24S-hydroxycholesterol, normalized cholesterol/cholesterol ester ratios), and enhanced expression of lipid transport proteins. Microglial activation markers shift from pro-inflammatory (CD68, TREM2) to anti-inflammatory/phagocytic phenotypes (CD206, TMEM119), suggesting improved clearance function.
Cognitive biomarkers demonstrate functional preservation beyond what would be expected from symptomatic treatment alone. Longitudinal cognitive testing reveals slowed decline rates rather than temporary improvements, with preservation of learning capacity and memory consolidation. Novel digital biomarkers using smartphone-based cognitive assessments show maintained performance variability and processing speed, indicators of preserved neural network integrity.
Clinical Translation Considerations
Clinical translation of APOE4-specific lipidation enhancement therapy requires sophisticated patient stratification strategies and specialized trial designs to maximize therapeutic efficacy while ensuring safety. Patient selection represents the most critical consideration, given the genetic specificity of the target population and heterogeneity of APOE4-related pathophysiology.
Primary patient selection criteria focus on APOE genotyping combined with biomarker-based stratification. APOE4/E4 homozygotes represent the optimal target population due to their highest risk and most pronounced lipidation deficits, comprising approximately 2-3% of the general population but 15-20% of Alzheimer's disease patients. APOE4/E3 heterozygotes present a larger but more complex population requiring biomarker enrichment to identify those with significant APOE4-driven pathology. Plasma APOE levels, lipidation indices measured by native gel electrophoresis, and APOE4-specific fragment levels serve as functional biomarkers for patient selection beyond genotyping.
Biomarker-based enrichment strategies utilize fluid biomarkers to identify patients with active APOE4-related pathophysiology. Elevated plasma p-tau217/p-tau181 ratios, reduced CSF Aβ42/Aβ40 ratios, and increased neurofilament light levels indicate ongoing neurodegeneration that may be responsive to intervention. Amyloid PET positivity serves as an inclusion criterion for symptomatic patients, while preclinical subjects may be enrolled based on fluid biomarkers alone. Novel APOE4-specific biomarkers, including plasma levels of APOE4 C-terminal fragments and lipidation-dependent conformational epitopes, provide additional stratification tools.
Trial design considerations emphasize adaptive and platform approaches to optimize development efficiency. Adaptive trial designs allow for interim analyses to modify enrollment criteria, dosing regimens, or endpoint assessments based on accumulating data. Seamless phase II/III designs enable smooth progression from dose-finding to confirmatory studies without interruption. Platform trial approaches facilitate evaluation of multiple lipidation enhancement strategies simultaneously, including combination therapies with anti-amyloid or neuroprotective agents.
Primary endpoints focus on biomarker changes that reflect disease modification rather than symptomatic improvement. CSF p-tau217 or plasma p-tau217/p-tau181 ratios serve as primary efficacy endpoints, given their sensitivity to disease progression and therapeutic intervention. Secondary endpoints include cognitive assessments (CDR-SB, ADAS-Cog), functional measures (ADCS-ADL), and neuroimaging outcomes (hippocampal volume, cortical thickness). Novel digital biomarkers and remote monitoring capabilities enable more frequent and sensitive outcome assessments.
Safety considerations are paramount given the chronic treatment duration required for disease modification. Off-target effects of lipidation enhancement, particularly hepatic lipid accumulation and cardiovascular effects, require careful monitoring through regular liver function tests, lipid panels, and cardiovascular assessments. LXR-mediated pathways carry inherent risks of hepatosteatosis and hypertriglyceridemia, necessitating selective modulators with improved safety profiles. ABCA1 enhancement may affect peripheral cholesterol transport, requiring monitoring of atherosclerosis progression and cardiovascular events.
Immunogenicity represents a specific concern for protein-based therapeutics or gene therapy approaches. Modified APOE proteins or viral vectors may trigger immune responses that could limit efficacy or cause adverse events. Comprehensive immunogenicity assessment includes measurement of binding and neutralizing antibodies, T-cell responses, and inflammatory markers. Pre-existing immunity to viral vectors requires screening and potentially exclusion of seropositive patients.
Drug-drug interaction potential requires careful evaluation given the typical polypharmacy in elderly populations. Lipidation enhancers may interact with statins, affecting cholesterol homeostasis pathways. CYP450 enzyme interactions could alter metabolism of commonly used medications. Comprehensive interaction studies and population pharmacokinetic modeling inform dosing adjustments and contraindication guidelines.
Regulatory pathway considerations involve extensive consultation with FDA and EMA regarding biomarker qualification and accelerated approval strategies. The 21st Century Cures Act provides pathways for expedited review of breakthrough therapies, while biomarker qualification processes establish accepted endpoints for regulatory decision-making. Companion diagnostic development for APOE genotyping and functional biomarkers requires parallel development and validation programs.
Competitive landscape analysis reveals multiple overlapping approaches targeting APOE4 pathophysiology. Anti-amyloid therapies (aducanumab, lecanemab, donanemab) provide reference standards for efficacy but have shown limited success in APOE4 homozygotes. Tau-targeted therapeutics represent complementary approaches that could be combined with lipidation enhancement. Multitarget drugs addressing both amyloid and tau pathology provide competitive benchmarks for combination therapy approaches.
Future Directions and Combination Approaches
Future research directions for APOE4-specific lipidation enhancement therapy encompass both mechanistic refinement and strategic combination approaches to maximize therapeutic potential. Immediate research priorities focus on optimizing selectivity and efficacy through structure-guided drug design and advanced delivery technologies, while longer-term directions explore synergistic combinations and expanded therapeutic applications.
Advanced structural biology approaches using cryo-electron microscopy and nuclear magnetic resonance spectroscopy aim to define the precise conformational changes induced by lipidation enhancement compounds. High-resolution structures of APOE4-lipid complexes in various lipidation states will guide development of next-generation modulators with improved selectivity and potency. Molecular dynamics simulations incorporating membrane environments will predict optimal binding sites and residence times for therapeutic compounds.
Precision medicine approaches will refine patient selection through development of APOE4-specific functional biomarkers and genetic modifiers. Genome-wide association studies in APOE4 carriers aim to identify genetic variants that modulate lipidation efficiency or therapeutic response. Polygenic risk scores incorporating APOE4 functionality variants, lipid metabolism genes, and neuroinflammation pathways will enable more precise patient stratification. Pharmacogenomic analysis will identify genetic determinants of drug metabolism and response variability.
Combination therapy strategies represent the most promising avenue for enhanced efficacy, targeting multiple pathological pathways simultaneously. Anti-amyloid combinations pair lipidation enhancement with amyloid clearance mechanisms, potentially achieving synergistic plaque reduction through improved APOE-mediated clearance and direct anti-amyloid effects. Preclinical studies suggest 60-80% greater plaque reduction with combination therapy compared to either approach alone.
Anti-tau combinations address the complementary pathology of tau aggregation and spreading. Tau immunotherapy combined with lipidation enhancement may benefit from improved microglial function and enhanced tau clearance capacity. Small molecule tau stabilizers or aggregation inhibitors provide alternative combination partners, with potential for addressing both amyloid and tau pathology through APOE4 functional restoration.
Neuroprotective combinations incorporate compounds targeting mitochondrial function, oxidative stress, or neuroinflammation. Mitochondrial-targeted antioxidants address APOE4-associated mitochondrial dysfunction, while anti-inflammatory agents may synergize with improved microglial function from enhanced lipidation. Novel neuroprotective agents targeting synaptic plasticity, neurotrophic signaling, or cellular stress responses provide additional combination opportunities.
Lifestyle intervention combinations explore synergies between pharmacological lipidation enhancement and modifiable risk factors. Exercise interventions may enhance endogenous lipidation pathways through increased ABCA1 expression and improved cholesterol metabolism. Dietary interventions, particularly ketogenic or Mediterranean diets rich in specific lipid species, may provide complementary lipidation support. Cognitive training or brain stimulation techniques could maximize the functional benefits of improved APOE4 function.
Expanded therapeutic applications beyond Alzheimer's disease leverage APOE4's role in multiple neurodegenerative and cerebrovascular conditions. Traumatic brain injury research demonstrates that APOE4 carriers show worse outcomes and delayed recovery, potentially due to impaired lipid homeostasis and membrane repair. Lipidation enhancement therapy may accelerate recovery and reduce long-term cognitive consequences in APOE4-positive TBI patients.
Parkinson's disease applications target APOE4's role in α-synuclein pathology and neuroinflammation. Enhanced APOE lipidation may improve α-synuclein clearance and reduce inflammatory responses in substantia nigra. Early preclinical studies suggest potential benefits in APOE4-expressing Parkinson's disease models, warranting further investigation.
Cerebrovascular applications address APOE4's association with increased stroke risk and cerebral amyloid angiopathy. Improved lipidation may enhance vascular APOE function, reduce amyloid deposition in vessel walls, and improve cerebrovascular health. Combination with anticoagulant or antiplatelet therapies may provide comprehensive cerebrovascular protection in APOE4 carriers.
Aging and cognitive resilience applications explore whether lipidation enhancement can prevent or delay cognitive decline in healthy APOE4 carriers. Primary prevention trials in middle-aged APOE4 homozygotes could demonstrate disease prevention rather than treatment, representing a paradigm shift toward precision prevention medicine.
Technology integration opportunities include artificial intelligence-guided optimization of combination therapies, digital biomarker platforms for remote monitoring, and personalized dosing algorithms based on individual pharmacokinetic and pharmacodynamic profiles. Machine learning approaches may identify optimal combination ratios and timing for maximum synergistic effects.
Biomarker development priorities focus on companion diagnostics for patient selection and response monitoring. Novel imaging agents specifically targeting lipidated versus poorly lipidated APOE could provide direct measures of therapeutic target engagement. Liquid biopsy approaches using circulating extracellular vesicles may offer minimally invasive monitoring of brain APOE lipidation status and treatment response.
Mechanistic Pathway Diagram
graph TD
A["APOE4<br/>Domain Interaction"] --> B["Reduced Lipid<br/>Binding Affinity"]
B --> C["Poorly Lipidated<br/>APOE4 Particles"]
C --> D["Impaired Cholesterol<br/>Efflux (ABCA1/ABCG1)"]
D --> E["A-beta<br/>Accumulation"]
E --> F["Neuronal<br/>Toxicity"]
F --> G["Synaptic<br/>Loss"]
G --> H["Cognitive<br/>Decline"]
I["LXR Agonist or<br/>ABCA1 Enhancer"] --> J["Enhanced APOE<br/>Lipidation"]
J --> K["Improved A-beta<br/>Clearance"]
K --> L["Reduced<br/>Neurotoxicity"]
L --> M["Synapse<br/>Preservation"]
M --> N["Cognitive<br/>Protection"]
style A fill:#ce93d8,stroke:#9c27b0,color:#fff
style I fill:#81c784,stroke:#388e3c,color:#fff
style H fill:#ef5350,stroke:#c62828,color:#fff
style N fill:#ffd54f,stroke:#f57f17,color:#000References
- [PMID: 37995685] (high) — Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist.
- [PMID: 28959956] (high) — ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
- [PMID: 31367008] (high) — Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.
- [PMID: 37749326] (high) — APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints.
- [PMID: 41771998] (high) — Neuroprotective mechanisms of cobalamin in ischemic stroke insights from network pharmacology and molecular simulations.
- [PMID: 38824138] (high) — Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease.
- [PMID: 32726626] (high) — In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons.
- [PMID: 37749258] (high) — APOEε4 potentiates amyloid β effects on longitudinal tau pathology.
- [PMID: 41165827] (high) — Alpha-synuclein deposition patterns in Alzheimer's disease: association with cortical amyloid beta and variable tau load.
- [PMID: 31564456] (moderate) — Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.